Glenmede Trust’s Array Biopharma Inc ARRY Stock Holding History

Glenmede Trust’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,000	Closed	-$138	–	3210
2019 Q2	$138	Sell	3,000 -5,085	-63%	-$143K	﹤0.01%	1304
2019 Q1	$197	Sell	8,085 -4,155	-34%	-$86.5K	﹤0.01%	1182
2018 Q4	$174	Buy	12,240 +1,855	+18%	+$28.1K	﹤0.01%	1165
2018 Q3	$157K	Buy	10,385 +3,650	+54%	+$55.9K	﹤0.01%	1215
2018 Q2	$113K	Buy	+6,735	New	+$107K	﹤0.01%	1234
2016 Q3	–	Sell	-900	Closed	-$3K	–	2724
2016 Q2	$3K	Sell	900 -500	-36%	-$1.63K	﹤0.01%	2354
2016 Q1	$4K	Hold	1,400	–	–	﹤0.01%	2290
2015 Q4	$5K	Hold	1,400	–	–	﹤0.01%	2288
2015 Q3	$6K	Hold	1,400	–	–	﹤0.01%	2269
2015 Q2	$10K	Buy	+1,400	New	+$10.3K	﹤0.01%	2110

Other funds holding ARRY

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Glenmede Trust's ARRY Position: Q3 2019 in Review

Glenmede Trust sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 3,000 shares — an estimated $138 sold.

Glenmede Trust first reported a position in ARRY in Q2 2015 and held it in 10 quarters. The position peaked at $157K in Q3 2018. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

Glenmede Trust reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
Glenmede Trust sold 3,000 Array Biopharma Inc shares in Q3 2019, an estimated $138.
Glenmede Trust first reported a position in Array Biopharma Inc in Q2 2015 and held it in 10 quarters.
Glenmede Trust's Array Biopharma Inc position peaked at $157K in Q3 2018.
1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Glenmede Trust's 13F filing for Q3 2019, filed 14 Nov 2019.